Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Jane E WilloughbyLang DouSabyasachi BhattacharyaHeather JacksonLaura Seestaller-WehrDavid KilianLaura BoverKui S VooKerry L CoxTom MurrayMel JohnHong ShiPaul BojczukJunping JingHeather NiedererAndrew J ShepherdLaura HookStephanie HopleyTatyana InzhelevskayaChris A PenfoldC Ian MockridgeVikki EnglishSara J BrettRoopa SrinivasanChristopher HopsonJames SmothersAxel HoosElaine PaulStephen L MartinPeter J MorleyNiranjan YanamandraMark S CraggPublished in: Journal for immunotherapy of cancer (2024)
These findings underline the importance of understanding the role of isotype in the mechanism of action of therapeutic mAbs. As an hIgG1, the anti-hOX40 mAb can elicit multiple mechanisms of action that could aid or hinder therapeutic outcomes, dependent on the microenvironment. This should be considered when designing potential combinatorial partners and their FcγR requirements to achieve maximal benefit and improvement of patient outcomes.